MPH Health Care Past Earnings Performance
Past criteria checks 3/6
MPH Health Care has been growing earnings at an average annual rate of 22.1%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been declining at an average rate of 1.7% per year. MPH Health Care's return on equity is 11.8%, and it has net margins of 85.8%.
Key information
22.1%
Earnings growth rate
22.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -1.7% |
| Return on equity | 11.8% |
| Net Margin | 85.8% |
| Next Earnings Update | 05 Sep 2024 |
Recent past performance updates
Recent updates
If You Had Bought MPH Health Care's (ETR:93M) Shares A Year Ago You Would Be Down 28%
Aug 10
What Type Of Returns Would MPH Health Care's(ETR:93M) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Aug 10We Think MPH Health Care's (ETR:93M) Statutory Profit Might Understate Its Earnings Potential
Jul 06
Revenue & Expenses Breakdown
How MPH Health Care makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 34 | 30 | 1 | 0 |
| 30 Sep 23 | 33 | 40 | 1 | 0 |
| 30 Jun 23 | 31 | 50 | 1 | 0 |
| 31 Mar 23 | 31 | 39 | 1 | 0 |
| 31 Dec 22 | 31 | 29 | 1 | 0 |
| 30 Sep 22 | 10 | -20 | 1 | 0 |
| 30 Jun 22 | -11 | -68 | 1 | 0 |
| 31 Mar 22 | 1 | -39 | 1 | 0 |
| 31 Dec 21 | 14 | -9 | 1 | 0 |
| 30 Sep 21 | 18 | -12 | 1 | 0 |
| 30 Jun 21 | 22 | -14 | 1 | 0 |
| 31 Mar 21 | 13 | -42 | 1 | 0 |
| 31 Dec 20 | 3 | -70 | 1 | 0 |
| 30 Sep 20 | 20 | -37 | 1 | 0 |
| 30 Jun 20 | 38 | -3 | 1 | 0 |
| 31 Mar 20 | 39 | 4 | 1 | 0 |
| 31 Dec 19 | 41 | 11 | 1 | 0 |
| 30 Sep 19 | 19 | -13 | 1 | 0 |
| 30 Jun 19 | -3 | -37 | 1 | 0 |
| 31 Mar 19 | 21 | 0 | 1 | 0 |
| 31 Dec 18 | 45 | 37 | 1 | 0 |
| 30 Sep 18 | 64 | 63 | 1 | 0 |
| 30 Jun 18 | 84 | 90 | 1 | 0 |
| 31 Mar 18 | 59 | 61 | 1 | 0 |
| 31 Dec 17 | 34 | 32 | 1 | 0 |
| 30 Sep 17 | 22 | 45 | 1 | 0 |
| 30 Jun 17 | 10 | 58 | 0 | 0 |
| 31 Mar 17 | 10 | 69 | 1 | 0 |
| 31 Dec 16 | 9 | 80 | 1 | 0 |
| 30 Sep 16 | 83 | 90 | 3 | 0 |
| 30 Jun 16 | 156 | 100 | 5 | 0 |
| 31 Mar 16 | 210 | 91 | 7 | 0 |
| 31 Dec 15 | 263 | 83 | 8 | 0 |
| 30 Sep 15 | 239 | 43 | 9 | 0 |
| 30 Jun 15 | 214 | 3 | 10 | 0 |
| 31 Mar 15 | 217 | 4 | 8 | 0 |
| 31 Dec 14 | 219 | 5 | 6 | 0 |
| 30 Sep 14 | 226 | 6 | 6 | 0 |
| 30 Jun 14 | 232 | 7 | 0 | 0 |
| 31 Mar 14 | 229 | 7 | 0 | 0 |
| 31 Dec 13 | 227 | 6 | 6 | 0 |
| 30 Sep 13 | 223 | 9 | 3 | 0 |
Quality Earnings: 93M1 has high quality earnings.
Growing Profit Margin: 93M1's current net profit margins (85.8%) are lower than last year (95.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 93M1's earnings have grown significantly by 22.1% per year over the past 5 years.
Accelerating Growth: 93M1's earnings growth over the past year (1.5%) is below its 5-year average (22.1% per year).
Earnings vs Industry: 93M1 earnings growth over the past year (1.5%) exceeded the Pharmaceuticals industry 1.5%.
Return on Equity
High ROE: 93M1's Return on Equity (11.8%) is considered low.